Apple (AAPL) has enjoyed a pretty remarkable run over the last decade. Ever since Apple introduced the iPod in 2001, the company has seen shares jump over 5,000 percent. The company now exists in some truly rarefied air, with questions abound as to whether or not the company's massive gains can be held over time. One firm, though, appears to think that Apple's gains are just beginning.
Brian White of Topeka Capital Markets has set a price target for Apple of $1,001 a share, an additional 61.8 percent higher than the firm's already sky-high share price. “Apple fever is spreading like a wildfire around the world.” said White, adding “We see no end in sight to this trend” White's price target may garner plenty of skepticism from other analysts, but it has at least put Topeka Captial Markets on the map in the short term.
Rambus (RMBS) Partners with Fern Howard
Technology licensing firm Rambus has signed a deal with Fern Howard, a market-leader in the manufacture of energy-efficient lighting technology. This deal will allow Fern to sell products that utilize Rambus lighting patents involving Rambus' MicroLens optics technology.
“We are excited to see Rambus lighting solutions expand into the European and Middle Eastern markets with the help of Fern Howard,” said president of the Lighting and Display Technology business at Rambus Jeff Parker. “Using key Rambus technologies, Fern Howard fixtures will achieve a level of styling, application efficiency, and precise control of light unmatched in the bulkhead and utility lighting industry.”
VIVUS (VVUS) Awaits Results
April looks to be a make-or-break month for biopharmaceutical company VIVUS. The company is awaiting the approval decisions for two different drugs, one an obesity treatment and the other for erectile dysfunction, that could mean major profits for the Mountain View, CA-based company. Qnexa, the pending obesity drug, has been watched with the closest scrutiny. If it receives FDA approval, it would become the first drug of its kind to garner FDA approval in more than ten years.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer